Indacaterol 150 μg capsules

Phase 3

Novartis AG (NVS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Obstructive Pulmonary Disease (COPD)

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial

NCT00794157

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/30/2009

Hirobriz Breezhaler

Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

View on EMA

EMA11/29/2009

Oslif Breezhaler

Oslif Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

View on EMA

EMA11/29/2009

Onbrez Breezhaler

Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Aflibercept 2 mgPhase 3

Neovascular Age-related Macular Degeneration

Certican®Phase 3

Renal Interstitial Fibrosis